This study was undertaken to evaluate the levels of cAMP-regulated phosphoproteins in the striatum of patients with neurodegenerative diseases of the dopaminergic system. Postmortem samples of caudate nucleus and putamen from 24 control subjects, 23 patients with Parkinson disease, and 13 patients with progressive supranuclear palsy were studied with immunoblotting techniques. The levels of tyrosine hydroxylase were reduced in patients with Parkinson disease (levels were 24% and 10% of controls in caudate nucleus and putamen, respectively) and with progressive supranuclear palsy (levels were 11% and 6% of controls in caudate nucleus and putamen, respectively). Five phosphoproteins, which are present in striatal neurons and are likely to play a role in the postsynaptic actions of dopamine, were measured. These
protein of Mr 32,000), and phosphatase inhibitor I. The levels of these phosphoproteins were inversely correlated with postmortem delay. In brains of patients with Parkinson disease or progressive supranuclear palsy with postmortem delays comparable to those of controls, the levels of these proteins as well as those of synaptic (synapsin I and synaptophysin) and glial (glial fibrillary acidic protein and myelin basic protein) markers were not significantly modified. We conclude that the levels of several phosphoproteins involved in signal transduction in striatal neurons are not altered in Parkinson disease and progressive supranuclear palsy. This observation supports the view that the striatal output neurons are intact in both diseases. Parkinsonian syndromes are caused by an impairment of dopaminergic transmission in the neostriatum (1) . In idiopathic Parkinson disease this impairment is due to a selective degeneration of the nigrostriatal dopaminergic neurons, and treatment by L-dopa dramatically improves the motor deficit during the first years after manifestation of the disease (1) . In progressive supranuclear palsy [Steele, Richardson, Olszewski syndrome (2) ], in addition to the lesions of the dopaminergic neurons, degeneration occurs in other regions of the brainstem and in the pallidum, a fact thought to account for the lack of efficiency of L-dopa in this disease (3) . In both diseases there is no gross anatomical alteration in the striatum, although histological and biochemical evidence suggests a specific deficit of the cholinergic interneurons in progressive supranuclear palsy (4, 5) . Little information is available concerning the status of the main target of the nigrostriatal pathway, the medium-sized spiny neurons. The question of functional and/or degenerative alterations in striatal dopaminoceptive neurons, secondary to degeneration of the dopaminergic neurons, is an important issue to address because the basic assumption oftreatment by dopaminergic agonists is that striatal neurons are functionally intact and able to respond to dopamine.
Dopamine activates adenylate cyclase through D1 receptors (6) . Increased cAMP levels result in the activation of cAMP-dependent protein kinase, which phosphorylates a variety of proteins in nervous tissue, some of which are specifically enriched in the medium-sized spiny neurons of the neostriatum (refs. 7 and 8; E. Gustafson and P.G., unpublished observations). Among these proteins, DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of Mr 32,000), ARPP-16, and ARPP-21 (cAMP-regulated phosphoproteins ofMr 16,000 and 21,000, respectively) have been purified (7, 9, 10) . Protein phosphatase inhibitor I and ARPP-19, two phosphoproteins that are closely related to DARPP-32 (7) and ARPP-16 (9), respectively, but which are more widely distributed, are also present in striatonigral neurons (11, 12) . All these proteins are phosphorylated by cAMP-dependent protein kinase and either have been shown to be (7), or are likely to be, involved in the effects of dopamine, acting through D1 dopamine receptors on striatal neurons. Hence they represent excellent probes for assessing the integrity of the striatal neurons, and, in particular, the integrity of their signal transduction machinery. The specificity of possible changes in the levels of these proteins was addressed by the simultaneous measurement of several other markers. Tyrosine hydroxylase was used as an index of the disappearance of dopaminergic fibers. Synapsin I and synaptophysin (also called P38) were used as markers of the nerve terminals (13 (15) . The criteria used for the diagnosis of progressive supranuclear palsy were the clinical record and the existence of typical lesions upon neuropathological examination (5) . The premortem severity index (14) Abbreviations: ARPP-16, -19, -21, cAMP-regulatedphosphoproteins of Mr 16,000, 19,000, and 21,000, respectively; DARPP-32, dopamine-and cAMP-regulated phosphoproteins.
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was a clinical index taking into account the degree of hypoxia and hypovolemia just before death. Postmortem delay was defined as the time interval between death and freezing of the brain. Brains were stored at -70TC until dissection (5) .
Measurement of Proteins of Interest. Brain samples (12-45 mg) were homogenized in boiling 2% (wt/vol) NaDodSO4 by sonication and further maintained in a boiling-water bath for 10 min. Protein concentrations were determined with BCA reagent (Pierce; uses bicinchoninic acid) using bovine serum albumin as standard. Equal amounts of protein were added to "stop solution" and boiled; 100-,ug aliquots were then subjected to polyacrylamide gel electrophoresis in the presence of NaDodSO4 (concentration of polyacrylamide, 13%) (16) and transferred to nitrocellulose (pore size, 0.2 gm; Schleicher & Schuell) (17) . The transferred proteins were fixed in isopropanol/acetic acid/water (1:1:8) and stained with amido black or Ponceau red for identification of molecular weight standards and possible transfer artifacts. In preliminary experiments the migration of the proteins of interest was determined, and in most subsequent experiments nitrocellulose filters were cut according to the position of molecular weight markers to incubate only the relevant part of the filter with the corresponding antibody. This approach allowed the study of several proteins from the same gel, a valuable procedure when starting material was available in limited amounts. Dyes were removed before immunoblotting by use of either 8 M urea and bovine serum albumin (200 mg/ml) at 60TC for 1 hr for amido black or 0.2 mM NaOH at room temperature for 5 min for Ponceau red.
Immunoblotting was performed at room temperature as described (18) , using nonfat dry milk as blocking agent (19 7, and 9 ). Experimental procedures were as described in the legend for Fig. 1 . In many cases the levels of TH were more markedly decreased in the putamen than in the caudate nucleus (e.g., lanes 5 and 9). brain extracts on every gel. The radioactivity measured increased linearly with the amount of protein (either purified standards or tissue homogenates) in the range studied (data not shown).
Another phosphoprotein enriched in the striatonigral neurons, ARPP-21, could not be assayed by immunoblot, because of its poor yield of transfer to nitrocellulose. Therefore ARPP-21 was measured by in vitro phosphorylation with the catalytic subunit of cAMP-dependent protein kinase (a gift of A. C. Nairn) and [-32P]ATP followed by immunoprecipitation with a specific antiserum (G154) as described (20) . Comparison of data obtained from immunoblots and phosphorylation/immunoprecipitation for ARPP-16, ARPP-19, and DARPP-32 showed that the two methods gave similar results (data not shown).
RESULTS
The proteins from human brain appeared to have properties (immunoreactivity, Mr values) qualitatively similar to those previously described for the corresponding proteins from rodent or bovine brain (Fig. 1) . Moreover two-dimensional proteolytic mapping of ARPP-16, ARPP-19, ARPP-21, and DARPP-32 from human brains, phosphorylated with cAMPdependent protein kinase, yielded phosphopeptides similar to those obtained from purified bovine proteins, further demonstrating their close structural similarities (data not shown). However, variations in the levels of these proteins were observed from one human brain to another, especially for DARPP-32 (Figs. 2 and 3) , ARPP-16, ARPP-19, and inhibitor I, whereas these proteins are found at very constant levels in the brains of experimental animals. This variability could not be accounted for by heterogeneity in microdissection because in several cases two different samples from the same caudate nucleus were measured and gave comparable results (data not shown). Furthermore, in control brains, levels of these proteins in the putamen and in the caudate nucleus from the same individuals correlated (DARPP-32, r = 0.894, P < 0.001; ARPP-16, r = 0.692, P < 0.005; ARPP-19, r = 0.452, P < 0.10; inhibitor I, r = 0.711, P < 0.002). Correlations between the levels of all proteins studied and several clinical parameters (sex, age of the patient, duration of the disease, interval between the cessation of L-dopa therapy and death, premortem severity index, and postmortem delay) were computed for each group of patients. The only significant correlations observed were between the levels of the striatal neuron-enriched phosphoproteins and postmortem delays ( Table 2) .
Given this inverse correlation, only brains with postmortem delays <24 hr were used for further study (Figs. 2 and 3 , Table 3 ). These brains had comparable average postmortem delays ( Table 3 ). The levels of tyrosine hydroxylase were decreased in the caudate nucleus and putamen of both Parkinson disease and progressive supranuclear palsy (Figs.  2 and 3 ). In contrast, the levels of DARPP-32, ARPP-16, ARPP-19, ARPP-21, and inhibitor I were not significantly altered in patients with either disease (Figs. 2 and 3 and Table  3 ). There was no significant correlation between the levels of tyrosine hydroxylase and those ofany ofthe phosphoproteins studied (data not shown). Furthermore, synaptic vesicleassociated phosphoproteins synapsin I and synaptophysin and glial markers were also unchanged (Table 3) .
DISCUSSION
In the present work with postmortem brain samples, it was important to consider the stability ofthe biochemical markers studied. In fact, the levels of striatal-enriched phosphoproteins decreased with postmortem time, indicating that these proteins may be very sensitive to proteolysis after death.
The amounts of tyrosine hydroxylase detected by immunoblot were markedly decreased in both Parkinson disease and progressive supranuclear palsy. This decrease reflects the degeneration of dopaminergic terminals in these two diseases and is in agreement with the decrease in tyrosine hydroxylase activity (3, 22) . In contrast, no significant change occurred in the levels of DARPP-32 or of any other proteins studied in the brains of patients with Parkinson disease or progressive supranuclear palsy. The normal levels of nerve terminal-associated proteins, despite the disappearance of the dopaminergic fibers, is not surprising because these fibers probably account for only a small fraction of the total number of terminals in the striatum (23) .
The present results are at variance with previously reported observations in which DARPP-32 levels, estimated by endogenous phosphorylation with cAMP-dependent protein kinase present in the homogenates, were found to be decreased (24) . There are several possible explanations for this discrepancy. The results observed in the previous study may have been affected by various endogenous inhibitors or phosphatases present in the assay, by variations in the levels of endogenous cAMP-dependent protein kinase, and most probably by differences in postmortem delays (which were significantly longer for parkinsonian patients than for controls). 
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The lack of change in DARPP-32, despite degeneration of dopaminergic neurons, seen in Parkinson disease and progressive supranuclear palsy agrees with observations in rat, where acute 6-hydroxydopamine lesions of the substantia nigra resulted in no change of DARPP-32 (25) or of its mRNA (M. S. Schalling, M. Ehrlich, T. Hokfelt, and P. G., unpublished observations). Similarly, chronic treatment ofrats with SCH 23390, a specific Dl-type dopamine receptor antagonist, did not induce any significant change in the levels ofDARPP-32, ARPP-16, ARPP-19, or synapsin I (J. A. Grebb, J.-A.G., and P.G., unpublished work). Our results are also consistent with reports of the absence of change in the levels of Dl-type dopamine receptors (15, 24) , glutamic acid decarboxylase, y-aminobutryic acid, and several neuropeptides (22) in the striatum of patients with Parkinson disease or progressive supranuclear palsy. However, in the latter disease restricted lesions of large cholinergic interneurons may exist (4, 5) and account, at least in part, for the decrease in striatal D2-type dopamine receptors (15) . All these observations indicate that the medium-sized spiny neurons, which represent the output neurons of the striatum, do not bear any detectable lesion in Parkinson disease and in progressive supranuclear palsy, even in advanced stages. In particular, several phosphoproteins, which are likely to mediate some of the effects of dopamine acting through D1-type dopamine receptors, are present at normal levels in both diseases.
